NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

PURPOSE: NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ademuyiwa, Foluso O., Bshara, Wiam, Attwood, Kristopher, Morrison, Carl, Edge, Stephen B., Ambrosone, Christine B., O’Connor, Tracey L., Levine, Ellis G., Miliotto, Anthony, Ritter, Erika, Ritter, Gerd, Gnjatic, Sacha, Odunsi, Kunle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386262/
https://www.ncbi.nlm.nih.gov/pubmed/22761704
http://dx.doi.org/10.1371/journal.pone.0038783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386262/
https://www.ncbi.nlm.nih.gov/pubmed/22761704
http://dx.doi.org/10.1371/journal.pone.0038783

Ejemplares similares